Fisher & Paykel Healthcare says the second half of the financial year is in line with the first, given a drop in the number of respiratory interventions associated with Omicron as well as a mild flu season in the Northern Hemisphere.
The Vitera device for sleep apnoea made by Fisher and Paykel. (file pic) Photo: Supplied / Fisher and Paykel Healthcare
At current dollar exchange rates, the respiratory health care manufacturer expected operating revenue for the full year ending in March to be in a range of $1.675 billion to $1.70b, which compared with $1.97b last year.
"In our homecare product group, growth in sales of our OSA (obstructive sleep apnoea) masks is currently tracking above our first half growth rate despite supply constraints of treatment hardware in the market," chief executive Lewis Gradon said.
"Freight rates remain elevated and for the 2022 financial year are expected to impact our long-term gross margin target of 65 percent by approximately 250 basis points."
Gradon said the company was well placed to respond to Covid-19.
"Regardless of how Covid-19 effects unfold over the short term, we are confident our business is well-placed to contribute to a positive change in clinical practice and improving outcomes for respiratory patients in general over the long term," he said.
The company plans to release its full year result on 25 May.